Reply to Fišer et al.: Myeloid reprogramming of Ph+ B-ALL: A potential therapeutic strategy.

Proc Natl Acad Sci U S A 2015 Jul 11;112(27):E3456. Epub 2015 Jun 11.

Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305.

Download full-text PDF

Source
http://www.pnas.org/lookup/doi/10.1073/pnas.1509027112
Publisher Site
http://dx.doi.org/10.1073/pnas.1509027112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500202PMC
July 2015

Publication Analysis

Top Keywords

ph+ b-all
4
b-all potential
4
potential therapeutic
4
therapeutic strategy
4
myeloid reprogramming
4
reprogramming ph+
4
fišer myeloid
4
reply fišer
4
therapeutic
1
strategy
1
myeloid
1
potential
1
reply
1
b-all
1
reprogramming
1
ph+
1

Similar Publications

Reprogramming of B cell acute lymphoblastic leukemia cells: Do we need to shoot a moving target?

Proc Natl Acad Sci U S A 2015 Jul 11;112(27):E3455. Epub 2015 Jun 11.

Childhood Leukemia Investigation Prague (CLIP), Second Faculty of Medicine, Charles University Prague and University Hospital Motol, 150 06 Prague, Czech Republic;

View Article and Full-Text PDF
July 2015

Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages.

Proc Natl Acad Sci U S A 2015 Mar 16;112(13):4074-9. Epub 2015 Mar 16.

Departments of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, and

BCR-ABL1(+) precursor B-cell acute lymphoblastic leukemia (BCR-ABL1(+) B-ALL) is an aggressive hematopoietic neoplasm characterized by a block in differentiation due in part to the somatic loss of transcription factors required for B-cell development. We hypothesized that overcoming this differentiation block by forcing cells to reprogram to the myeloid lineage would reduce the leukemogenicity of these cells. We found that primary human BCR-ABL1(+) B-ALL cells could be induced to reprogram into macrophage-like cells by exposure to myeloid differentiation-promoting cytokines in vitro or by transient expression of the myeloid transcription factor C/EBPα or PU. Read More

View Article and Full-Text PDF
March 2015

Advances in the molecular pathobiology of B-lymphoblastic leukemia.

Hum Pathol 2012 Sep 8;43(9):1347-62. Epub 2012 May 8.

Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.

B-lymphoblastic leukemia/lymphoma, also known as B-acute lymphoblastic leukemia, is derived from B-cell progenitors. B-acute lymphoblastic leukemia occurs predominantly in children, but can occur at any age. Risk-adapted intensive chemotherapy is effective in treating most children with B-acute lymphoblastic leukemia, but this approach is less successful in adults. Read More

View Article and Full-Text PDF
September 2012